4-乙氧基吡啶n-氧化物 | 14474-56-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 4-乙氧基吡啶n-氧化物
• 英文名称: 4-ethoxypyridine-N-oxide
• 英文别名: 4-ethoxypyridine 1-oxide；4-ethoxypyridine N-oxide；4-ethoxy-pyridine-1-oxide；4-Aethoxy-pyridin-1-oxid；4-ethoxy-1-oxidopyridin-1-ium
• CAS: 14474-56-7
• 化学式: C₇H₉NO₂
• mdl: MFCD00023414
• 分子量: 139.154
• InChiKey: OWDMBYMZBXLZFT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.285
• 拓扑面积：
  34.7
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  4-乙氧基吡啶n-氧化物 在 溶剂黄146 、 锌 作用下， 反应 1.0h， 以91%的产率得到4-乙氧基吡啶
  参考文献：
  名称：

  2-氨基-1,3,5-三嗪化学：氢键网络，竹本硫脲催化剂类似物和甜味三嗪的嗅觉图

  摘要：

  摘要研究了具有庞大烷基取代基的4,6-二烷基-2-氨基-1,3,5-三嗪的化学性质，并探讨了它们作为制备手性硫脲有机催化剂的基础。氨与4,6-二叔丁基-2-氯-1,3,5-三嗪反应生成4,6-二叔丁基-1,3,5-三嗪-2-胺根据X射线晶体学分析，氢键网络处于固态。将选定的杂环胺转化为异硫氰酸酯，后者与（S，S）-2-（二甲基氨基）环己胺反应，生成对映体纯的1-杂芳基-3- [2-（二甲基氨基）环己基]硫脲，杂芳基代表4， 6-二甲基-1,3-二嗪-2-基，4,6-二异丙基-1,3,5-三嗪-2-基或4,6-二叔丁基-1,3,5-三嗪-2-基-丁基。这些化合物是Takemotos手性硫脲有机催化剂（1- [3,5-双（三氟甲基）苯基] -3-[（1 S，2 S）-2-（二甲基氨基）环己基]硫脲）的结构类似物。而不是3,5-双（三氟甲基）苯基。它们具有强大的分子内N–H至N-1氢键，如1-（4

  DOI：

  10.1007/s00706-015-1515-7
• 作为产物：
  描述：

  吡啶-N-氧化物 在 硫酸 、 硝酸 作用下， 生成 4-乙氧基吡啶n-氧化物
  参考文献：
  名称：

  den Hertog; Combe, Recueil des Travaux Chimiques des Pays-Bas, 1951, vol. 70, p. 581,587

  摘要：

  DOI：
• 作为试剂：
  描述：

  3,5-dimethoxybenzoin 在 四氮唑 、 叔丁基过氧化氢 、 二氯乙酸 、 4-乙氧基吡啶n-氧化物 、 triisopropylbenzenesulfonyl chloride 作用下， 以 异辛烷 、 二氯甲烷 、 1,2-二氯乙烷 、 乙腈 为溶剂， 生成 [(2R,3S,5R)-2-[[tert-butyl(diphenyl)silyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl] [(2R,3S,5R)-3-[2-cyanoethoxy-[1-(3,5-dimethoxyphenyl)-2-oxo-2-phenylethoxy]phosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl 2-cyanoethyl phosphate
  参考文献：
  名称：

  Inverse Phosphotriester DNA Synthesis Using Photochemically-Removable Dimethoxybenzoin Phosphate Protecting Groups

  摘要：

  A method has been developed to prepare short DNA sequences using light to deprotect a nucleoside 3'-phosphotriester, generating a phosphodiester useful for coupling with a free 5'-OH-nucleotide. The dimethoxybenzoin group is used as the photochemically-removable protecting group for the 3'-phosphate. Cyanoethyl is most effective as the second protecting group on the phosphodiester. Because the method is directed at the preparation and use of the DNA sequences while still bound to the support, allyl and allyloxycarbonyl protecting groups are used for the nitrogenous bases since, based on the work of Hayakawa and Noyori, they can be removed without cleaving the DNA from the support. Two simple trinucleotides have been prepared in solution using this method. It has been demonstrated that the photochemical deprotection conditions do not lead to the formation of cyclobutane dimers from adjacent T residues.

  DOI：

  10.1021/jo951593c

文献信息

• [EN] PYRIDINE DERIVATIVES AS REARRANGED DURING TRANSFECTION (RET) KINASE INHIBITORS<br/>[FR] DÉRIVÉS PYRIDINE UTILISÉS COMME INHIBITEURS DE LA KINASE RÉARRANGÉE AU COURS DE LA TRANSFECTION (RET)
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2014141187A1

  公开（公告）日：2014-09-18

  This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, Von Hippel-Lindau Syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased RET kinase activity.

  这项发明涉及一种新型化合物，它们是重排基因转位（RET）激酶的抑制剂，包括含有它们的药物组合物，它们的制备方法，以及它们在治疗中的使用，单独或结合使用，用于规范胃肠敏感性、蠕动和/或分泌以及/或腹部紊乱或疾病的治疗，或与与RET功能障碍相关的疾病相关的治疗，或者调节RET活性可能具有治疗益处的治疗，包括但不限于所有分类的肠易激综合征（IBS），包括以腹泻为主、以便秘为主或交替排便模式、功能性腹胀、功能性便秘、功能性腹泻、未特指的功能性肠道障碍、功能性腹痛综合征、慢性特发性便秘、功能性食管障碍、功能性胃十二指肠障碍、功能性肛门疼痛、炎症性肠病、非小细胞肺癌、肝细胞癌、结肠癌、髓样甲状腺癌、滤泡性甲状腺癌、间变性甲状腺癌、乳头状甲状腺癌、脑肿瘤、腹腔癌、实体肿瘤、其他肺癌、头颈癌、神经胶质瘤、神经母细胞瘤、冯·希普-林道综合征和肾肿瘤、乳腺癌、输卵管癌、卵巢癌、移行细胞癌、前列腺癌、食管和胃食管交界处癌症、胆道癌、腺癌，以及任何具有增加RET激酶活性的恶性肿瘤。
• [EN] NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS UTILISÉS COMME INHIBITEURS DE LA KINASE RÉARRANGÉE AU COURS DE LA TRANSFECTION (RET)
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2016037578A1

  公开（公告）日：2016-03-17

  This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, Von Hippel-Lindau Syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased RET kinase activity.

  这项发明涉及一种新型化合物，这些化合物是重排转位过程中的抑制剂（RET）激酶，包含它们的药物组合物，它们的制备方法，以及它们在治疗中的使用，单独或结合使用，用于规范胃肠敏感性、蠕动和/或分泌以及/或腹部紊乱或疾病和/或与RET功能障碍相关的疾病或调节RET活性可能具有治疗益处的治疗，包括但不限于所有分类的肠易激综合征（IBS），包括以腹泻为主、以便秘为主或交替排便模式、功能性腹胀、功能性便秘、功能性腹泻、未特指的功能性肠道障碍、功能性腹痛综合征、慢性特发性便秘、功能性食管障碍、功能性胃十二指肠障碍、功能性肛门疼痛、炎症性肠病、非小细胞肺癌、肝细胞癌、结肠癌、髓样甲状腺癌、滤泡性甲状腺癌、间变性甲状腺癌、乳头状甲状腺癌、脑肿瘤、腹腔癌、实体肿瘤、其他肺癌、头颈癌、神经胶质瘤、神经母细胞瘤、冯·希普-林道氏综合征和肾肿瘤、乳腺癌、输卵管癌、卵巢癌、移行细胞癌、前列腺癌、食管和食管胃交界处癌症、胆道癌、腺癌，以及任何具有增加RET激酶活性的恶性肿瘤。
• BENZAZEPINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1422228A1

  公开（公告）日：2004-05-26

  The present invention provides a novel benzazepine derivative represented by formula : wherein, R1 is a 5- or 6-membered aromatic ring, R2 is lower alkyl group, etc., Y is an optionally substituted imino group, ring A and ring B are independently an optionally substituted aromatic ring, W is formula -W1-X2-W2- (W1 and W2 are independently S(O)m1 (m1 is 0, 1 or 2), etc., and X2 is an optionally substituted alkylene groupetc. ), a preparation method and use thereof.

  本发明提供了一种新型的苯并氮杂环衍生物，其由以下公式表示： 其中，R1是一个5-或6-成员的芳香环，R2是低级烷基团等，Y是可选地取代的亚氨基，环A和环B是独立地选自一个可选地取代的芳香环，W是公式-W1-X2-W2-（W1和W2是独立地为S(O)m1（m1是0、1或2）等，X2是一个可选地取代的亚烷基团等），其制备方法及其用途。
• Synthesis of <i>N</i>-(2-pyridyl)imidazolidin-2-ones and 1-(2-pyridyl)-2,3,7,8-tetrahydro-1<i>H</i>-imidazo[2,1-<i>b</i>][1,3,5]triazepin-5(6<i>H</i>)-ones with potential biological activities
  作者：Łukasz Balewski、Franciszek Sączewski、Maria Gdaniec、Patrick J. Bednarski、Izabela Jara

  DOI：10.1515/hc-2013-0125

  日期：2013.10.1

  1-(2-pyridyl)imidazolidin-2-one and 1-(2-pyridyl)-2,3,7,8-tetrahydro-1H-imidazo[2,1-b]- [1,3,5]triazepin-5(6H)-one derivatives were prepared from substituted pyridine or quinoline N-oxides and 2-chloro-4,5-dihydroimidazole by means of the α-ureation and α-amination reactions. The α-ureation reaction of pyridine and quinoline N-oxides was studied theoretically by means of quantum chemical calculations

  摘要 1-(2-pyridyl)imidazolidin-2-one 和 1-(2-pyridyl)-2,3,7,8-四氢-1H-imidazo[2,1-b]- [1,3 ,5]三氮杂-5(6H)-one衍生物由取代的吡啶或喹啉N-氧化物和2-氯-4,5-二氢咪唑通过α-脲化和α-胺化反应制备。通过密度泛函理论水平的量子化学计算，从理论上研究了吡啶和喹啉N-氧化物的α-脲化反应。筛选了新获得的化合物对人肿瘤细胞系 LCLC-103H、5637 和 A-427 的潜在体外细胞毒活性。
• Benzazepine derivative, process for producing the same, and use
  申请人：——

  公开号：US20040235822A1

  公开（公告）日：2004-11-25

  The present invention provides a novel benzazepine derivative represented by formula: 1 wherein, R 1 is a 5- or 6-membered aromatic ring, R 2 is lower alkyl group, etc., Y is an optionally substituted imino group, ring A and ring B are independently an optionally substituted aromatic ring, W is formula —W 1 —X 2 —W 2 — (W 1 and W 2 are independently S(O) m1 (m1 is 0, 1, or 2), etc., and X 2 is an optionally substituted alkylene group etc.), a preparation method and use thereof.

  本发明提供了一种新型苯并氮杂环衍生物，其化学式表示为：1其中，R1为5-或6-成员芳香环，R2为低碳基，Y为可选取代的亚胺基，环A和环B分别为可选取代的芳香环，W为式—W1—X2—W2—（其中W1和W2分别为独立的S(O)m1（m1为0、1或2）等，X2为可选取代的烷基等），以及其制备方法和用途。